FDA Approved: EVEROLIMUS — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Everolimus submitted by Hikma Pharmaceuticals USA Inc. This action updates approved labeling and/or indications …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer
• Pancreatic Neuroendocrine Tumor
• Renal Cell Carcinoma
• Subependymal Giant Cell Astrocytoma
• Tuberous Sclerosis Complex-associated Renal Angiomyolipoma

Drugs mentioned

• Everolimus (everolimus)

Snippet

SUPPL AP for EVEROLIMUS (EVEROLIMUS)